Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting
MWN-AI** Summary
Pharvaris, a late-stage biopharmaceutical firm, is set to present significant clinical data at the upcoming AAAAI 2026 Annual Meeting in Philadelphia, PA, scheduled from February 27 to March 2, 2026. The company will showcase six accepted abstracts, including three during the Featured Poster session. This presentation marks Pharvaris' first major opportunity to share positive topline results from the RAPIDe-3 study, announced in December 2025.
Dr. Peng Lu, Chief Medical Officer at Pharvaris, emphasized the importance of this meeting for disseminating the company's findings to the broader medical community. Among the key presentations will be final results from the open-label portion of CHAPTER-1, a Phase 2 study focusing on deucrictibant as a prophylactic treatment for hereditary angioedema (HAE). Additional presentations will include pharmacokinetic data for the new extended-release formulation of deucrictibant, intended for long-term prophylaxis in the ongoing Phase 3 CHAPTER-3 study, with topline data expected later in 2026.
Highlights of the presentations will include advanced findings on a novel kinin biomarker assay, validation of the angioedema symptom rating scale (AMRA), and data showcasing the impact of deucrictibant on health-related quality of life for HAE patients.
Pharvaris is committed to addressing unmet needs within bradykinin-mediated diseases, including HAE and acquired angioedema due to C1 inhibitor deficiency. By developing oral bradykinin B2 receptor antagonists with injectable-like efficacy, the company aims to set new standards in managing these conditions while facilitating easier and more convenient treatment options. As they prepare for critical marketing authorization applications and ongoing pivotal studies, Pharvaris continues to advance its mission to improve patient outcomes in the realm of angioedema treatment.
MWN-AI** Analysis
Pharvaris (Nasdaq: PHVS) is positioned at a critical junction in its development of deucrictibant, an oral bradykinin B2 receptor antagonist aimed at addressing the unmet needs of patients with hereditary angioedema (HAE) and acquired angioedema. The company’s upcoming presentations at the AAAAI 2026 Annual Meeting mark a significant opportunity to share promising data from recent clinical studies, particularly the Phase 2 CHAPTER-1 open-label extension study and the Phase 3 RAPIDe-3 study.
Investors should closely monitor Pharvaris, especially as the backdrop of recent topline data announcement enhances the significance of these presentations. The data discussed, particularly regarding long-term prophylactic treatment and quality of life improvements in HAE patients, could serve as pivotal points for increased market interest and investor confidence leading up to the release of Phase 3 data in Q3 2026.
As the company prepares global marketing authorization applications for the immediate-release formulation of deucrictibant, the strength of the clinical data presented will likely influence regulatory trajectories and market perceptions. Participants at the meeting will witness the innovative approaches Pharvaris is implementing to validate their kinin biomarker assay and patient-reported outcome measures that enrich treatment perspectives.
However, potential investors should also consider inherent risks, as delays in regulatory approvals or disappointing Phase 3 data could lead to volatility in the stock price. Adopting a cautious approach—buying smaller positions while maintaining ongoing analysis of market sentiment and clinical results—may mitigate risk while allowing for participation in potential upside from Pharvaris’ advancements.
In summary, Pharvaris represents a compelling opportunity for those with a high-risk tolerance willing to engage with a biopharma poised for potential breakthroughs in treating bradykinin-mediated diseases. Market participants should ensure they remain updated on the results from the AAAAI meeting and future trial data releases.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
ZUG, Switzerland, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced the acceptance of six abstracts for poster presentation, three of which will be presented during the Featured Poster session, at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting, to be held from February 27-March 2, 2026, in Philadelphia, PA.
“Following the announcement of topline RAPIDe-3 data in December of last year, the AAAAI Annual Meeting provides Pharvaris with the first opportunity to share the positive study results with the broader medical community at a large scientific congress,” said Peng Lu, M.D., Ph.D., Chief Medical Officer of Pharvaris. “We will also be presenting final data from the open-label portion of CHAPTER-1, the Phase 2 study of deucrictibant for prophylaxis of HAE attacks, and pharmacokinetic data of deucrictibant extended-release tablet, which is being used in the pivotal Phase 3 study of deucrictibant for long-term prophylaxis of HAE attacks, CHAPTER-3. Final efficacy and safety results from approximately three years of deucrictibant treatment from CHAPTER-1 and the data providing further evidence of an optimized extended-release formulation provide strong foundations in advance of the results of CHAPTER-3, topline data from which is anticipated in the third quarter of this year. Additionally, we will be presenting on-demand endpoint validation findings, as well as results from our novel kinin biomarker assay.”
Details of the presentations are as follows:
- Title: A Novel Kinin Biomarker Assay for Characterization of Different Types of Bradykinin-Mediated Angioedema
Presenter: Evangelia Pardali, Ph.D.
Poster Number: 078
Date, time: Friday, February 27, 2026, 2:45-3:45 p.m. EST - Title: Content Validity of the Angioedema syMptom Rating scAle (AMRA) to Assess Symptoms of Hereditary Angioedema Attacks
Presenter: Teresa Caballero, M.D., Ph.D.
Poster Number: 154
Date, time: Friday, February 27, 2026, 2:45-3:45 p.m. EST - Title: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Health-Related Quality of Life in Participants with Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study
Presenter: Michael E. Manning, M.D.
Poster Number: 159
Date, time: Friday, February 27, 2026, 2:45-3:45 p.m. EST - Title: Oral Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Study
Presenter: Marc A. Riedl, M.D., M.S.
Featured Poster Number: 831
Date, time: Sunday, March 1, 2026, 3:30-5:00 p.m. EST - Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study
Presenter: John Anderson, M.D.
Featured Poster Number: 832
Date, time: Sunday, March 1, 2026, 3:30-5:00 p.m. EST - Title: Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
Presenter: Zhi-Yi Zhang, Ph.D.
Featured Poster Number: 834
Date, time: Sunday, March 1, 2026, 3:30-5:00 p.m. EST
The abstracts are available to view in an online supplement to The Journal of Allergy and Clinical Immunology (JACI) at jacionline.org.
The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: ir.pharvaris.com/news-events/events-presentations.
About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. Pharvaris is preparing global marketing authorization applications for deucrictibant immediate-release capsule as an on-demand treatment of HAE attacks, and a global pivotal Phase 3 study of deucrictibant extended-release tablet for the prevention of HAE attacks (CHAPTER-3) is ongoing with topline data anticipated in the third quarter of 2026. In addition, CREAATE is an ongoing Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks. For more information, visit https://pharvaris.com/.
ContactMaggie BellerExecutive Director, Head of Corporate and Investor Communicationsmaggie.beller@pharvaris.com
FAQ**
How does Pharvaris N.V. PHVS plan to leverage the positive topline RAPIDe-3 data at the AAAAI 2026 Annual Meeting to enhance investor confidence and market interest in their bradykinin B2 receptor antagonists?
What specific outcomes from the CHAPTER-3 study of Pharvaris N.V. PHVS are anticipated in Q3 2026, and how might these results impact the company's future stock performance?
Can Pharvaris N.V. PHVS provide insights into the commercialization strategy for deucrictibant following global marketing authorization applications for its therapies targeting hereditary angioedema?
How will the presentation of the novel kinin biomarker assay and other research at the AAAAI 2026 Annual Meeting influence the future research and development strategy of Pharvaris N.V. PHVS in bradykinin-mediated diseases?
**MWN-AI FAQ is based on asking OpenAI questions about Pharvaris N.V. (NASDAQ: PHVS).
NASDAQ: PHVS
PHVS Trading
-0.75% G/L:
$26.52 Last:
61,376 Volume:
$26.94 Open:
